Author/Authors :
Luo, Xuefeng Department of Gastroenterology and Hepatology - West China Hospital - Sichuan University, Chengdu, China , Wang, Wanqin Department of Gastroenterology and Hepatology - West China Hospital - Sichuan University, Chengdu, China , Fan, Xiaoli Department of Gastroenterology and Hepatology - West China Hospital - Sichuan University, Chengdu, China , Zhao, Ying Department of Gastroenterology and Hepatology - West China Hospital - Sichuan University, Chengdu, China , Wang, Xiaoze Department of Gastroenterology and Hepatology - West China Hospital - Sichuan University, Chengdu, China , Yang, Jinlin Department of Gastroenterology and Hepatology - West China Hospital - Sichuan University, Chengdu, China , Yang, Li Department of Gastroenterology and Hepatology - West China Hospital - Sichuan University, Chengdu, China
Abstract :
Background and Aim
The outcome of cirrhotic patients with main portal vein occlusion and portal cavernoma after the first episode of acute variceal bleeding (AVB) is unknown. We compared short-term outcomes after AVB in cirrhotic patients with and without portal cavernoma.
Methods
Between January 2009 and September 2014, 28 patients with cirrhosis and portal cavernoma presenting with the first occurrence of AVB and 56 age-, sex-, and Child-Pugh score-matched cirrhotic patients without portal cavernoma were included. The primary endpoints were 5-day treatment failure and 6-week mortality.
Results
The 5-day treatment failure rate was higher in the cavernoma group than in the control group (32.1% versus 12.5%; p = 0.031). The 6-week mortality rate did not differ between the cavernoma and control group (25% versus 12.5%, p = 0.137). Multivariable Cox proportional hazard regression analyses revealed that 5-day treatment failure (HR = 1.223, 95% CI = 1.082 to 1.384; p = 0.001) independently predicted 6-week mortality.
Conclusions
Cirrhotic patients with AVB and portal cavernoma have worse short-term prognosis than patients without portal cavernoma. The 5-day treatment failure was an independent risk factor for 6-week mortality in patients with cirrhosis and portal cavernoma